Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cabaletta Bio

1.30
+0.01501.17%
Volume:208.39K
Turnover:266.80K
Market Cap:65.71M
PE:-0.55
High:1.31
Open:1.25
Low:1.23
Close:1.28
Loading ...

BRIEF-Cabaletta Bio Announces Updated Clinical Data With Rese-Cel At February Scientific Meetings

Reuters
·
18 Feb

Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses Across Multiple Indications With Rese-Cel at February Scientific Meetings

THOMSON REUTERS
·
18 Feb

Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings

GlobeNewswire
·
18 Feb

Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February

GlobeNewswire
·
11 Feb

Cabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference

GlobeNewswire
·
29 Jan

Cabaletta Bio Price Target Maintained With a $25.00/Share by HC Wainwright & Co.

Dow Jones
·
17 Jan

William Blair Remains a Buy on Cabaletta Bio (CABA)

TIPRANKS
·
14 Jan

BRIEF-Cabaletta Bio Outlines Strategic Priorities And Anticipated Key Milestones For 2025

Reuters
·
13 Jan

Cabaletta Bio Inc: Unaudited Cash and Cash Equivalents as of Dec 31, 2024 Was $164 Mln

THOMSON REUTERS
·
13 Jan

Cabaletta Bio : Expects Cash Position as of Dec 31, 2024, Will Enable It to Fund Its Updated Operating Plan Into First Half of 2026

THOMSON REUTERS
·
13 Jan

Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025

THOMSON REUTERS
·
13 Jan

Cabaletta Bio Inc - Caballetta to Meet FDA on Rese-Cel Trial Designs in 1H25

THOMSON REUTERS
·
13 Jan

Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025

GlobeNewswire
·
13 Jan

Analysts Conflicted on These Healthcare Names: Verastem (VSTM), Roche Holding AG (OtherRHHVF) and Cabaletta Bio (CABA)

TIPRANKS
·
21 Dec 2024

BofA Securities Cuts Price Target on Cabaletta Bio to $29 From $31, Keeps Neutral Rating

MT Newswires Live
·
20 Dec 2024

Evercore ISI Downgrades Cabaletta Bio to In Line From Outperform, Cuts Price Target to $6 From $15

MT Newswires Live
·
20 Dec 2024

Cabaletta Bio downgraded at Evercore ISI on lack of financing clarity

TIPRANKS
·
20 Dec 2024

Cabaletta Bio downgraded to In Line from Outperform at Evercore ISI

TIPRANKS
·
20 Dec 2024

Wells Fargo Downgrades Cabaletta Bio to Equalweight From Overweight, Cuts Price Target to $6 From $12

MT Newswires Live
·
19 Dec 2024

Cabaletta Bio downgraded to Equal Weight from Overweight at Wells Fargo

TIPRANKS
·
19 Dec 2024